Lipum AB Logo

Lipum AB

Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.

LIPUM | ST

Overview

Corporate Details

ISIN(s):
SE0015660899 (+1 more)
LEI:
549300V7JL0004BHBD93
Country:
Sweden
Address:
Tvistevägen 48 C, 907 36 Umeå
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel treatments for chronic inflammatory diseases. The company's lead candidate, SOL-116, is a first-in-class humanized antibody that offers a unique mechanism of action by targeting the protein bile salt-stimulated lipase (BSSL). Lipum's primary goal is to address unmet medical needs and improve the quality of life for patients suffering from conditions such as rheumatoid arthritis (RA). The company has successfully completed its First-in-Human (FIH) Phase I clinical trial for SOL-116, with findings supporting continued development towards a potential new therapy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Lipum AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Lipum AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Lipum AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-14 Peter Hovstadius Other Sell 2,000 28,260.00 SEK
2025-04-14 Peter Hovstadius Other Sell 1,500 22,770.00 SEK
2025-04-14 Peter Hovstadius Other Sell 1,500 21,030.00 SEK

Peer Companies

Company Country Ticker View
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America AVBP
ARROWHEAD PHARMACEUTICALS, INC. Logo
Develops RNAi medicines to silence genes causing intractable cardiometabolic and pulmonary diseases.
United States of America ARWR
ARS Pharmaceuticals, Inc. Logo
Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.
United States of America SPRY
ARTELO BIOSCIENCES, INC. Logo
Develops lipid-signaling therapeutics for cancer, pain, anxiety, and depression.
United States of America ARTL
Artiva Biotherapeutics, Inc. Logo
Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.
United States of America ARTV
Ascelia Pharma Logo
Develops novel drugs for rare oncology, including an oral MRI contrast agent for cancer patients.
Sweden ACE
Ascendis Pharma A/S Logo
Biopharma using proprietary TransCon® tech to develop therapies for rare diseases & oncology.
United States of America ASND
ASCENTAGE PHARMA GROUP INTERNATIONAL Logo
Biopharma developing small-molecule drugs for cancer, HBV, and age-related diseases.
United States of America AAPG

Talk to a Data Expert

Have a question? We'll get back to you promptly.